TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adalimumab for the Treatment of Perianal Fistulas in Crohn's Disease More Effective Alone or Combined to Ciprofloxacin
Brief Summary: To assess whether a combination of ciprofloxacin and adalimumab is more effective than adalimumab alone for the treatment of perianal fistulas in Crohn's disease


Options:
A: Arm Label: Any adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Any adalimumab
B: Arm Label: Open-label adalimumab (Week 0 to Week 4); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Open-label adalimumab (Week 0 to Week 4) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: ciprofloxacin | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ciprofloxacin; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile
Brief Summary: In this trial, FLOT will be evaluated as therapy option for elderly patients (\>65 years) with advanced gastric cancer in comparison to the well established FLO scheme. The hypothesis is that FLOT is more effective than FLO in elderly patients with acceptable side effects.


Options:
A: Arm Label: FLOT; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Drug: Leucovorin, Drug: Oxaliplatin, Drug: Docetaxel | Arm Label: ECF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Cisplatin, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ECF | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): ECF | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): ECF
B: Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): N/A
C: Arm Label: ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: ramucirumab, Other: Best Supportive Care (BSC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: ramucirumab; Assigned to Arm(s): ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo, ramucirumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile
Brief Summary: In this trial, FLOT will be evaluated as therapy option for elderly patients (\>65 years) with advanced gastric cancer in comparison to the well established FLO scheme. The hypothesis is that FLOT is more effective than FLO in elderly patients with acceptable side effects.


Options:
A: Arm Label: 1. PEP02; Type: EXPERIMENTAL; Interventions: Drug: PEP02 | Arm Label: 2. irinotecan; Type: ACTIVE_COMPARATOR; Interventions: Drug: irinotecan | Arm Label: 3. docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: PEP02; Assigned to Arm(s): 1. PEP02 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 2. irinotecan | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): 3. docetaxel
B: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2
D: Arm Label: Arm A (ECF + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: ECF | Arm Label: Arm B (IC + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: IC | Arm Label: ARM C (FOLFOX + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: FOLFOX | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): ARM C (FOLFOX + cetuximab), Arm A (ECF + cetuximab), Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: ECF; Assigned to Arm(s): Arm A (ECF + cetuximab) | Intervention Type: DRUG; Name: IC; Assigned to Arm(s): Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: FOLFOX; Assigned to Arm(s): ARM C (FOLFOX + cetuximab)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GORE VIABAHN® Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients
Brief Summary: The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis.


Options:
A: Arm Label: VIABAHN Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface | Arm Label: PTA Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty | Intervention Type: DEVICE; Name: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface; Assigned to Arm(s): VIABAHN Treatment Group | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): PTA Treatment Group
B: Arm Label: Balloon thrombectomy; Type: EXPERIMENTAL; Interventions: Device: Balloon thrombectomy | Arm Label: Thromboaspiration system; Type: EXPERIMENTAL; Interventions: Device: Thromboaspiration system | Intervention Type: DEVICE; Name: Balloon thrombectomy; Assigned to Arm(s): Balloon thrombectomy | Intervention Type: DEVICE; Name: Thromboaspiration system; Assigned to Arm(s): Thromboaspiration system
C: Intervention Type: PROCEDURE; Name: angioplasty; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: stent placement; Assigned to Arm(s): N/A
D: Arm Label: Conventional Balloon Angioplasty (COBA); Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: Drug Eluting Balloon Angioplasty (DEB); Type: EXPERIMENTAL; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Drug Eluting Balloon Angioplasty (DEB) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Conventional Balloon Angioplasty (COBA)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.
Brief Summary: The purpose of this study was to demonstrate that mesalazine 4g orally per day once daily (QD) is non-inferior to the reference regimen, mesalazine 4g per day in two divided doses (BID) (2g x 2 per day), in patients with active ulcerative colitis (UC) treated for 8 weeks, in terms of remission evaluated with the Ulcerative Colitis Disease Activity Index (UC-DAI) score and defined as less than or equal to 1. Both groups (4g QD and 2gx2) received an enema containing 1g of mesalazine at bedtime during the initial 4 weeks.

Participants in remission at week 8 received an additional 4 weeks of maintenance therapy with 2g oral mesalazine once a day. Participants who did not achieve remission at Week 8 completed the study at week 8.


Options:
A: Arm Label: Mesalazine once/day; Type: EXPERIMENTAL; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Arm Label: Mesalazine twice/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Intervention Type: DRUG; Name: Mesalazine slow-release granules; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day | Intervention Type: DRUG; Name: Mesalazine liquid enema; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day
B: Arm Label: Dersalazine; Type: EXPERIMENTAL; Interventions: Drug: Dersalazine sodium | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dersalazine sodium; Assigned to Arm(s): Dersalazine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Budesonide MMX; Type: EXPERIMENTAL; Interventions: Drug: Budesonide MMX®, Drug: 5-ASA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: 5-ASA | Intervention Type: DRUG; Name: Budesonide MMX®; Assigned to Arm(s): Budesonide MMX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-ASA; Assigned to Arm(s): Budesonide MMX, Placebo
D: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.
Brief Summary: The purpose of this study was to demonstrate that mesalazine 4g orally per day once daily (QD) is non-inferior to the reference regimen, mesalazine 4g per day in two divided doses (BID) (2g x 2 per day), in patients with active ulcerative colitis (UC) treated for 8 weeks, in terms of remission evaluated with the Ulcerative Colitis Disease Activity Index (UC-DAI) score and defined as less than or equal to 1. Both groups (4g QD and 2gx2) received an enema containing 1g of mesalazine at bedtime during the initial 4 weeks.

Participants in remission at week 8 received an additional 4 weeks of maintenance therapy with 2g oral mesalazine once a day. Participants who did not achieve remission at Week 8 completed the study at week 8.


Options:
A: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalazine | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): B
C: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
D: Arm Label: Mesalazine once/day; Type: EXPERIMENTAL; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Arm Label: Mesalazine twice/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Intervention Type: DRUG; Name: Mesalazine slow-release granules; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day | Intervention Type: DRUG; Name: Mesalazine liquid enema; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sleep Apnea cardioVascular Endpoints Study - Investigating the Effectiveness of Treatment With CPAP vs Standard Care in Reducing CV Morbidity and Mortality in Patients With Co-existing CV Disease and Moderate-severe Obstructive Sleep Apnea.
Brief Summary: Obstructive Sleep Apnea (OSA) is a condition in which a person stops breathing for several seconds at a time due to relaxation of the throat muscles. This can occur many times during sleep. It is known to cause sleepiness and poor concentration during the day. Research indicates that OSA may be a modifiable risk factor for cardiovascular disease due to its association with hypertension, stroke, heart attack and sudden death. The standard therapy for symptomatic OSA is continuous positive airway pressure (CPAP). CPAP has been shown to effectively reduce snoring, obstructive episodes and daytime sleepiness and to modestly reduce blood pressure and other risk factors for cardiovascular disease. The overall aim of SAVE is to determine if CPAP can reduce the risk of heart attack, stroke or heart failure for people with OSA.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): 2
B: Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Intensive care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive care | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive care; Assigned to Arm(s): Intensive care
C: Arm Label: Domiciliary group; Type: ACTIVE_COMPARATOR; Interventions: Other: Diagnosis and monitoring of OSA patients | Arm Label: Hospital Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Diagnosis and monitoring of OSA patients | Arm Label: Mixed Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Diagnosis and monitoring of OSA patients | Intervention Type: OTHER; Name: Diagnosis and monitoring of OSA patients; Assigned to Arm(s): Domiciliary group, Hospital Group, Mixed Group
D: Arm Label: Traditional; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine Education Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Education | Arm Label: Telemedicine IVR Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: IVR | Arm Label: Telemedicine Both Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Education, Behavioral: IVR | Intervention Type: BEHAVIORAL; Name: Telemedicine Education; Assigned to Arm(s): Telemedicine Both Pathway, Telemedicine Education Pathway | Intervention Type: BEHAVIORAL; Name: IVR; Assigned to Arm(s): Telemedicine Both Pathway, Telemedicine IVR Pathway

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sleep Apnea cardioVascular Endpoints Study - Investigating the Effectiveness of Treatment With CPAP vs Standard Care in Reducing CV Morbidity and Mortality in Patients With Co-existing CV Disease and Moderate-severe Obstructive Sleep Apnea.
Brief Summary: Obstructive Sleep Apnea (OSA) is a condition in which a person stops breathing for several seconds at a time due to relaxation of the throat muscles. This can occur many times during sleep. It is known to cause sleepiness and poor concentration during the day. Research indicates that OSA may be a modifiable risk factor for cardiovascular disease due to its association with hypertension, stroke, heart attack and sudden death. The standard therapy for symptomatic OSA is continuous positive airway pressure (CPAP). CPAP has been shown to effectively reduce snoring, obstructive episodes and daytime sleepiness and to modestly reduce blood pressure and other risk factors for cardiovascular disease. The overall aim of SAVE is to determine if CPAP can reduce the risk of heart attack, stroke or heart failure for people with OSA.


Options:
A: Arm Label: Fixed CPAP; Type: EXPERIMENTAL; Interventions: Device: Fixed CPAP | Arm Label: Auto-adjusting CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto-adjusting CPAP | Intervention Type: DEVICE; Name: Fixed CPAP; Assigned to Arm(s): Fixed CPAP | Intervention Type: DEVICE; Name: Auto-adjusting CPAP; Assigned to Arm(s): Auto-adjusting CPAP
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: constant CPAP devices | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: automatic CPAP devices | Intervention Type: DEVICE; Name: constant CPAP devices; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: automatic CPAP devices; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: BiPap auto with Fi Flex | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard CPAP | Intervention Type: DEVICE; Name: BiPap auto with Fi Flex; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Standard CPAP; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen.
Brief Summary: The purpose of the study was to evaluate the effect of Pamidronate on bone mineral density loss and fracture rates up to 2 years, in post renal-transplant subjects on a Ciclosporin A and glucocorticoid based immunosuppressive regimen.


Options:
A: Arm Label: Parmidronate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Parmidronate
B: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab (Prolia) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Denosumab (Prolia); Assigned to Arm(s): Denosumab
C: Arm Label: Postassium citrate; Type: EXPERIMENTAL; Interventions: Drug: Potassium citrate | Arm Label: Potassium chloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Potassium chloride | Intervention Type: DRUG; Name: Potassium citrate; Assigned to Arm(s): Postassium citrate | Intervention Type: DRUG; Name: Potassium chloride; Assigned to Arm(s): Potassium chloride
D: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A

Answer: A